Soleno Therapeutics

Soleno Therapeutics, Inc. engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. The firm focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.

REDWOOD CITY, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq:SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today the closing of the underwritten public offering of 3,450,000 shares of its common stock at a public offering price of $20.00 per share, which included the exercise in full by the underwriters of their option to purchase additional shares. The gross proceeds of the public offering were $69.0 million, before deducting the underwriting discount and other estimated offering expenses.   Soleno also announced the closing of approximately $60.0 million of shares of its common stock and pre-funded warrants in a concurrent private offering pursuant to the securities purchase agreement with certain investors, including entities affiliated with existing stockholders, at a price per share of common stock equal to the public offering price of $20.00 and a price per pre-funded warrant of $19.99. Adage Capital Partners LP, Commodore Capital, Frazier Life Sciences, Nantahala Capital, Perceptive Advisors, Woodline Partners LP, and other existing investors participated in the concurrent private placement.

Soleno Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

REDWOOD CITY, Calif., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq:SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today the pricing of the underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $20.00 per share. The gross proceeds of the public offering are expected to be approximately $60.0 million, before deducting the underwriting discount and other estimated offering expenses. Soleno has also granted the underwriters a 30-day option to purchase up to 450,000 shares of common stock at the public offering price, less underwriting discounts and commissions.

Soleno Therapeutics Announces Pricing of Approximately $120 Million Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and/or Pre-Funded Warrants

Soleno announced on Tuesday top-line results for its lead therapy candidate. The company said it plans to submit a New Drug Application to the FDA regarding diazoxide choline controlled-release (DCCR) to treat Prader-Willi Syndrome.

Why Shares of Soleno Therapeutics Dropped on Wednesday

REDWOOD CITY, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq:SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it intends to offer and sell shares of its common stock and/or pre-funded warrants in an underwritten public offering. In addition, Soleno intends to grant the underwriters a 30-day option to purchase an additional number of shares of common stock equal to 15% of the aggregate number of shares of its common stock and/or pre-funded warrants sold in the public offering. The public offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Soleno Therapeutics Announces Proposed Public Offering of Common Stock and/or Pre-Funded Warrants and a Concurrent Private Placement of Common Stock and/or Pre-Funded Warrants

The biotechnology company had announced positive study results for its DCCR tablets on Tuesday.

Soleno Stock Dives After Its Meteoric Rise

Soleno's (SLNO) shares rally as the late-stage study evaluating diazoxide choline for patients with Prader-Willi syndrome meets its primary and secondary endpoints.

Soleno (SLNO) Soars as Prader-Willi Syndrome Study Meets Goal

Soleno specializes in treating rare metabolic disorders. The company's lead therapy, DCCR, fared well as a treatment for Prader-Willi syndrome.

Why Shares of Soleno Therapeutics Are Booming on Tuesday

Soleno said Tuesday its experimental pill helped control hunger signals in a genetic disorder. In response, SLNO stock skyrocketed.

Soleno Catapults Almost 400% After Its Pill Controls Hunger In Obesity-Causing Genetic Disease

Soleno Therapeutics (NASDAQ: SLNO ) stock is rocketing higher on Tuesday after the biopharmaceutical company announced positive clinical trial data. The big news here is the company seeing statistically significant results from its long-term treatment study of DCCR.

Why Is Soleno Therapeutics (SLNO) Stock Up 420% Today?

Study Met Primary Endpoint; Highly Statistically Significant Difference in Change from Baseline in HQ-CT Total Score for DCCR Compared to Placebo (p=0.0022)

Soleno Therapeutics Announces Positive Statistically Significant Top-line Results from Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome

REDWOOD CITY, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present at the Cantor Global Healthcare Conference on Tuesday, September 26, 2023 at 8:10 AM Eastern Time.

Soleno Therapeutics to Present at the Cantor Global Healthcare Conference

REDWOOD CITY, Calif., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of Matthew Pauls, J.D., M.B.A, to its Board of Directors, effective August 15, 2023. Mr. Pauls is an accomplished industry veteran with extensive executive leadership, strategic and commercial experience.

Soleno Therapeutics Announces Appointment of Industry Veteran Matthew Pauls, J.D., M.B.A. to Board of Directors

REDWOOD CITY, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update and reported financial results for the second quarter ended June 30, 2023.

Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

REDWOOD CITY, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update and reported financial results for the first quarter ended March 31, 2023.

Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results

Top-line data expected in Q3 2023 and has the potential to support an NDA submission for DCCR in Prader Willi Syndrome

Soleno Therapeutics Completes Enrollment in Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome

REDWOOD CITY, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days on Monday, April 3, 2023 at 10:10 AM Eastern Time.

Soleno Therapeutics to Participate in the Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days

REDWOOD CITY, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the fourth quarter and full-year ended December 31, 2022.

Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results

REDWOOD CITY, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a fireside chat at Oppenheimer's 33rd Annual Healthcare Conference on Tuesday, March 14, 2023 at 11:20 AM Eastern Time.

Soleno Therapeutics to Participate in the Oppenheimer 33rd Annual Healthcare Conference

Elys Game Technology, Corp.

Gossamer Bio Inc

Kala Pharmaceuticals

Myomo

Oric Pharmaceuticals

Sitio Royalties Corp

While everyone knows that in order to have a market, there must be bulls and bears, that's not going to stop people from attempting to garner intense profits from top short-squeeze candidates. To quickly summarize, shorting stocks involves borrowing shares to initiate the “negative” position.

7 Top Short-Squeeze Candidates to Watch in February

REDWOOD CITY, Calif., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that results from the Company's previously completed Phase 3 DESTINY PWS (C601) trial of DCCR (Diazoxide Choline) Extended-Release tablets for the treatment of Prader-Willi Syndrome (PWS) have been published in a peer-reviewed journal. The article, entitled, “Diazoxide Choline Extended-Release Tablet in People with Prader-Willi Syndrome: A Double-Blind Placebo-Controlled Trial,” was published in The Journal of Clinical Endocrinology and Metabolism (JCEM) and can be found here.

Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome

Soleno Therapeutics, Inc. (SLNO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Soleno Therapeutics, Inc. (SLNO) Upgraded to Strong Buy: What Does It Mean for the Stock?

AcelRx Pharmaceuticals

These three penny (and nickel) stocks in the healthcare sector have a lot of potential for 2023, and definitely worth watching.

Three Healthcare Penny Stocks to Watch In The New Year

Though clinical-stage biopharmaceutical firm Soleno Therapeutics (NASDAQ: SLNO ) encountered more than its fair share of setbacks this year, it blitzed rival enterprises on Monday. Earlier this morning, management disclosed a securities purchase agreement with Nantahala Capital Management, Abingworth and Vivo Capital.

Why Is Soleno Therapeutics (SLNO) Stock Up 130% Today?

AGM Group Holdings Inc - Ordinary Shares - Class A

Assembly Biosciences

Ensysce Biosciences

Innate Pharma SA

LianBio

Hot penny stocks to watch with big news this week. The post Penny Stocks To Buy Now?

Penny Stocks To Buy Now? 6 To Watch With Big News Today

Funding from three leading healthcare investors, with Vivo Capital joining existing investors Nantahala Capital and Abingworth

News for Soleno Therapeutics Stock (SLNO)